Unit cost
Injections 0/0/0 0/0/0 7/7/0 7/7/0 7/7/0 7/7/0 7/7/0 7/7/0 £742.17
Laser 0/0/0 0/0/0 0/2/2 0/2/2 0/2/2 0/2/2 0/2/2 0/2/2 £274.19
Ophthalmologist 12/12/5 12/12/5 12/12/5 12/12/5 12/12/5 12/12/3 12/12/3 12/12/3 £74.10
Optometrist 12/12/5 12/12/5 12/12/5 12/12/5 12/12/5 12/12/3 12/12/3 12/12/3 £62.84 GP 1/1/1 1/1/1 1/1/1 2/2/2 2/2/2 2.5/2.5/2.5 2.5/2.5/2.5 2.5/2.5/2.5 £35.00
Nurse consultant 1/1/1 1/1/1 1/1/1 2/2/2 2/2/2 2.5/2.5/2.5 2.5/2.5/2.5 2.5/2.5/2.5 £60.92
Adjustment for doublecounting of monitoring visits 0/0/0 0/0/0 0/-2/-2 0/-2/-2 0/-2/-2 0/-2/-2 0/-2/-2 0/-2/-2 GP 1/1/1 1/1/1 1/1/1 2/2/2 2/2/2 2.5/2.5/2.5 2.5/2.5/2.5 2.5/2.5/2.5 £35.00
Adjustment for double-
Ophthalmologist cost=weighted average of 'ophthalmologist visit' and 'additional ophthalmologist visit in Supplementary Supplementary Table 1 .
Optometrist cost=weighted average of 'pre-injection VA and BCVA assessment' and 'optometrist visit' in Supplementary Supplementary Table 1. BCVA, best corrected visual acuity; GP, general practitioner; VA, visual acuity. 
Supplementary
Ophthalmologist 5/5/5 5/5/5 5/5/5 5/5/5 5/5/5 3/3/3 3/3/3 3/3/3 £74.10
Optometrist 5/5/5 5/5/5 5/5/5 5/5/5 5/5/5 3/3/3 3/3/3 3/3/3 £62.84 GP 1/1/1 1/1/1 1/1/1 2/2/2 2/2/2 2.5/2.5/2.5 2.5/2.5/2.5 2.5/2.5/2.5 £35.00
Nurse consultant 1/1/1 1/1/1 1/1/1 2/2/2 2/2/2 2.5/2.5/2.5 2.5/2.5/2.5 2.5/2. service is based on a population with age-related macular degeneration as a substitute for a DME population. Unit costs were updated using same method and source as Mead or inflated if no updated estimates were available. DME, daibetic macular oedema; NHS, National Health Service.
Supplementary Methods: Estimation of long-term change in BCVA (year 3 and onwards)
The long-term change in best corrected visual acuity (BCVA) is simulated with a simple model, which assumes there is a constant rate of change in visual acuity (VA). This rate is modelled by three parameters:
 improvement of ≥10 letters within 3 months  worsening of ≥10 letters within 3 months  no change exceeding 10 letters within 3 months (residual of the first two parameters).
There are only a few sources in the literature that report the progression of VA in patients with diabetic macular oedema (DME). The long-term assumptions have mainly been developed from the following two sources in combination with model calibration.
 Data from the DRCR.net protocol I study (Elman, 2010) , which showed that the improvement achieved after 12 months with combination therapy (ranibizumab plus laser therapy) and with laser monotherapy was maintained after 24 months. This is taken as an indication that the mean VA is stable in year 2.
 Observational data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) (Moss, 1988) , which show that the proportion of diabetic patients with a decrease in VA exceeds the proportion with an improvement 4years after onset. This is taken as an indication that VA tends to decrease.
Parameter values for worsening and improving of VA were calibrated with 4-years incidence of worsening and improving in the WESDR population. The health state 'BCVA 66-75 letters'
was selected for calibration because it represents the most common health state (39% at baseline); furthermore, this range overlaps with the range that was reported in WESDR (equivalent to 60-70 letters).
The reported 4-year incidence in WESDR may overstate the proportion of patients with a worsened VA because the WESDR population received less intensive systemic diabetes management than is current practice. The 4-year incidence was therefore adjusted to reflect more modern practice. Adjustments were guided by data derived from studies investigating the relationship between level of glycaemic control and the risk of developing microvascular complications such as diabetic retinopathy.
The Diabetes Control and Complications Trial (DCCT) (DCCT Trial Research Group, 1993) concluded that intensive therapy resulted in a 23% risk reduction of DME compared with conventional therapy (mean 6.5 years follow-up). The UK Prospective Diabetes Study 33 (UKPDS 33) reported a 25% risk reduction of microvascular endpoints when comparing intensive and conventional therapy (median 10 years follow-up). The UKPDS 35 study reported a 37% risk reduction per 1% reduction of HbA 1c , based on observational data. The UKPDS 68 study reported an odds ratio of 1.25 for HbA 1c as a predictor of blindness. From this evidence, we decided to adjust the 4-year incidence of worsened VA in the WESDR population by 25%, from 48% to 36%.
The calibration was performed by simulation of a population with an initial VA in the range 66-75 letters. The simulation predicts the incidence of improvement and worsening after 4 years by applying constant change rates to the population. The WESDR data do not include the effect of DME. For this reason, we chose to calibrate from baseline and to year 4 neglecting the progression in year 1 reported in RESTORE. Due to the DME effect, the laser arm in RESTORE showed worsening in 33% of the patients in year 1.
Inputs and outputs of the calibration process are shown in Supplementary Supplementary   Table 6 . The first column shows the result of using the rates of change from month 9 to month 12 in the laser group in RESTORE. The second column shows the result of assuming equal rates (0.03 worsening and 0.03 improving). The third column shows the best fit with WESDR.
If the rates in the laser arm in RESTORE were used, the model would overestimate the proportion with an improvement (0.32 vs 0.25) and underestimate the proportion with 10 worsening (0.23 vs 0.36) after 4 years. Adjusting the rates of change to be equal (0.03 worsening and 0.03 improving) improves the fit. However, the fit is even better when the rate of change is adjusted to 0.035 for improving and 0.045 for worsening. 
Supplementary

